Clinical trials: Disitamab Vedotin
Gastric Adenocarcinoma
A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
The goal of this clinical trial is to learn if the combination of disitamab vedotin, tunlametinib, and a PD-1 antibody works to treat HER2-overexpressing advanced gastric cancer in patients who have already received at least two…
- Trial name
- DTP-HER2 (NCT07507526)
- Testing
- Tunlametinib+PD-1 mAb
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sun Yat-sen University
Sebaceous Gland Carcinoma
A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant therapy with Sintilimab combined with Disitamab Vedotin in patients with locally advanced, resectable or potentially resectable sebaceous gland…
- Trial name
- NCT07740993
- Testing
- Sintilimab, disitamab vedotin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- West China Hospital
HER2-positive Gastric Cancer
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
A single-arm, single-center phase II trial study to assess the efficacy and safety of disitamab vedotin plus cadonilimab as first-line therapy for HER2-overexpressing advanced stomach carcinoma
- Trial name
- NCT06492317
- Testing
- Disitamab Vedotin, Cadonilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Colorectal Neoplasms
Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
Among patients with colonrectal cancer, 5% were HER-2 positive, but the immunohistochemical results were mostly HER-2 2 +, which did not meet the indications of HER-2 targeting drugs.
- Trial name
- NCT05493683
- Testing
- Disitamab vedotin, Tislelizumab
- Where
- 6 sites in China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Cancer, HER2-low-expressing Gastric Cancer
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
This is a single-arm, prospective, non-randomized, multi-center/single-center, open-label, phase I clinical study aimed at evaluating the efficacy and safety of Disitamab Vedotin in combination with PD-1 as posterior line…
- Trial name
- NCT06078982
- Testing
- Disitamab Vedotin, Toripalimab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai East Hospital
HER2-positive Gastric Cancer, Metastatic Gastric Cancer
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
This is a Phase II, randomized, multicenter, open-label clinical trial designed to compare Disitamab Vedotin plus Sintilimab and S-1 with Trastuzumab plus chemotherapy ± Sintilimab for first-line treatment of HER2-Positive…
- Conditions
- HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
- Trial name
- NCT06730373
- Testing
- Disitamab Vedotin, Sintilimab, S-1
- Where
- 20 sites in China
- Volunteers
- 110 people
- Sponsor
- Qilu Hospital of Shandong University
Gastric Cancer
Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
This study is a prospective, open label, phase II clinical study intended to include patients with locally advanced gastric adenocarcinoma who have not undergone any treatment and are eligible for surgery.
- Trial name
- NCT06487429
- Testing
- Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastric Cancer
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
This study aims to evaluate the efficacy of disitamab vedotin in combination with sintilimab and SOX as conversion therapy in patients with initially unresectable locally advanced or metastatic gastric cancer exhibiting HER2 IHC…
- Trial name
- Remission (NCT07194005)
- Testing
- Disitamab vedotin(RC48), Sintilimab, S-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
This study aims to evaluate the efficacy and safety of intravenous administration of vedacitinib combined with intravesical instillation of mitomycin in treating patients with high-risk NMIBC with HER2 expression.
- Trial name
- NCT07646145
- Testing
- Disitamab Vedotin, Mitomycin C (MMC)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanxi Province Cancer Hospital
HER2-positive Metastatic Breast Cancer, First-line Treatment
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
The goal of this multicentre, randomized, double-blind controlled, phase III clinical trial is to compare the efficacy and safety of disitamab vedotin in combination with pyrotinib versus the standard first-line treatment of…
- Trial name
- NCT06278870
- Testing
- disitamab vedotin, Pyrotinib, trastuzumab
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Prostate Cancer, CDK12 Gene Mutation
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
The aim of this study is to evaluate the efficacy and safety of vediximab monotherapy or in combination with enrolizumab for second-line treatment of CDK12 alterations mCRPC that has failed standard therapy.
- Trial name
- NCT06663007
- Testing
- RC48, Envafolimab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Tianjin Medical University Second Hospital
Urothelial Carcinoma
Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation
This is a prospective, open, single center clinical study of vidicizumab combined with local radiotherapy as bladder conserving therapy in patients with muscle invasive bladder urothelium cancer with HER-2 expression (IHC 2+or…
- Trial name
- NCT05912205
- Testing
- Disitamab Vedotin, radiotherapy
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Bladder (Urothelial, Transitional Cell) Cancer
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
This is a prospective, open label, multicenter clinical study of vediximab combined with PD-1 and radiation therapy for bladder preservation in MIBC patients with HER-2 high expression (IHC 2+or 3+), conducted in accordance with…
- Trial name
- DECIDING (NCT07142200)
- Testing
- Disitamab Vedotin, PD-1 inhibitor, radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- RenJi Hospital
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors
Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Disitamab Vedotin combined therapy locally advanced or metastatic NSCLC Patients with HER2 Alterations.
- Conditions
- Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48, Disitamab Vedotin
- Trial name
- NCT05847764
- Testing
- RC48+Tislelizumab+carboplatin, RC48+Furmonertinib, 1L, RC48+Furmonertinib, 2L+
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Sun Yat-sen University
Lung Cancer
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
The goal of this clinical trial is to learn ifDisitamab Vedotin in combination with tislelizumab and bevacizumab can treat in locally advanced or metastatic non-small cell lung cancer patients with HER2…
- Trial name
- NCT06749860
- Testing
- Disitamab Vedotin + tislelizumab + bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy, Upper Tract Urothelial Carcinoma
Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma
UTUC is a cancer that develops in the lining of the kidney or ureter. The standard treatment is radical nephroureterectomy, which removes the kidney and ureter.
- Trial name
- NCT07504939
- Testing
- SBRT
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Peking University First Hospital
Bladder Cancer
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer
This is a prospective, open-label, single-arm exploratory clinical study evaluating the efficacy and safety of disitamab vedotin (RC48) plus toripalimab with cetirizine and mecobalamin in patients with locally advanced…
- Trial name
- NCT07853053
- Testing
- Disitamab Vedotin, Toripalimab, Cetirizine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Disitamab Vedotin（RC48）combined with EGFR or HER2 TKIs in locally advanced or metastatic NSCLC Patients with HER2 Alterations.
- Conditions
- Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, ERBB2 Gene Duplication, Disitamab Vedotin
- Trial name
- NCT06185400
- Testing
- Disitamab Vedotin, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib), pyrotinib
- Volunteers
- 108 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
mCRPC
Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II Study
This is an open-label，prospective，single-arm，phase 2 trial aims to evaluate the efficacy and safety of disitamab vedotin combined with abiraterone in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT07093866
- Testing
- Disitamab Vedotin (RC48), Abiraterone + prednisone
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Advanced Gastric Carcinoma, HER2-positive Gastric Cancer
RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer
To explore the safety and clinical efficacy of cisplatin combined with RC48 and anti-PD-1 antibodies AK105 in Her-2 positive advanced gastric cancer.
- Trial name
- NCT05313906
- Testing
- RC48+AK105+cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital